Management of Myocardial Injury After Noncardiac Surgery Trial

Completed · Phase 3 · Has a placebo group

Conditions studied: Myocardial Injury After Noncardiac Surgery (MINS)

In brief

Patients who have myocardial injury after noncardiac surgery are at a higher risk of dying than those who do not. One in 10 patients with myocardial injury will die within 30 days of surgery. This risk of death exists up to one year after myocardial injury. There are currently no treatments or guidelines available for heart injury after surgery, but there is evidence that taking a blood-thinner can prevent some of the deaths, both in the short and long-term. The purpose of this trial is to test the effect of two drugs (dabigatran and omeprazole) that may prevent mortality, major cardiovascular complications and major upper gastrointestinal bleeding in patients who have had myocardial injury after noncardiac surgery.

Key facts

Study ID

NCT01661101

Run by

Population Health Research Institute

People needed

1754

Starts

2013-01-01

Expected to finish

2018-03-01

Last updated by the study team

2018-03-26

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients are eligible if they:
• have undergone noncardiac surgery;
• are ≥45 years of age;
• have suffered MINS based upon fulfilling one of the following criteria: A. Elevated troponin or CK-MB measurement with one or more of the following defining features i. ischemic signs or symptoms (i.e., chest, arm, neck, or jaw discomfort; shortness of breath, pulmonary edema); ii. development of pathologic Q waves present in any two contiguous leads that are ≥30 milliseconds; iii. electrocardiogram (ECG) changes indicative of ischemia (i.e., ST segment elevation [≥2 mm in leads V1, V2, or V3 OR ≥1 mm in the other leads], ST segment depression [≥1 mm], OR symmetric inversion of T waves ≥1 mm) in at least two contiguous leads; iv. new LBBB; or v. new or presumed new cardiac wall motion abnormality on echocardiography or new or presumed new fixed defect on radionuclide imaging B. Elevated troponin measurement after surgery with no alternative explanation (e.g., pulmonary embolism, sepsis) to myocardial injury; AND
• provide written informed consent to participate within 35 days of suffering their MINS.

You may not qualify if…

• Patients meeting any of the following criteria will be excluded:
• hypersensitivity or known allergy to dabigatran;
• history of intracranial, intraocular, or spinal bleeding;
• hemorrhagic disorder or bleeding diathesis;
• known hepatic impairment or liver disease expected to have an impact on survival;
• condition that requires therapeutic dose anticoagulation (e.g., prosthetic heart valve, venous thromboembolism, atrial fibrillation);
• currently using or plan to initiate rifampicin, cyclosporine, itraconazole, tacrolimus, ketoconazole, or dronedarone;
• women who are pregnant, breastfeeding, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study;
• investigator considers the patient unreliable regarding requirement for study follow-up or study drug compliance; OR
• previously enrolled in the MANAGE Trial.
• Also excluded will be patients in whom any of the following criteria persist beyond 35 days of their suffering MINS:
• the attending surgeon believes it is not safe to initiate therapeutic dose anticoagulation therapy;
• the attending physician believes ASA, intermittent pneumatic compression, or elastic stockings are not sufficient for venous thromboembolism (VTE) prophylaxis and that the patient requires a prophylactic-dose anticoagulant;
• the patient has an indwelling epidural or spinal catheter that cannot be removed, or the first dose of dabigatran will occur within 4 hours of epidural catheter removal; OR
• estimated glomerular filtration rate (eGFR) <35 ml/min as estimated by calculated creatinine clearance.
• it is expected that the patient will undergo cardiac catheterization for MINS.
• Exclusion Criteria Specific to Patients in the Omeprazole Factorial Component of the Trial:
• Patients meeting any of the following criteria:
• hypersensitivity or known allergy to omeprazole;
• requirement for a proton pump inhibitor, an H2-receptor antagonist, sucralfate, atazanavir, clopidogrel, or misoprostol;
• esophageal or gastric variceal disease; OR
• patient declines participation in the omeprazole arm of MANAGE.

Where it is running

• VA Western New York Healthcare System — Buffalo, New York, United States
• University of Rochester Medical Center — Rochester, New York, United States
• Wake Forest School of Medicine — Winston-Salem, North Carolina, United States
• Oregon Health and Science University — Portland, Oregon, United States
• Drexel University College of Medicine — Philadelphia, Pennsylvania, United States
• VA North Texas Health Care System Dallas VA Medical Center — Dallas, Texas, United States
• Instituto Cardiovascular de Buenos Aires — Caba, Buenos Aires, Argentina
• Clinica Parra - Centro de Investigaciones — Rafaela, Santa Fe Province, Argentina
• Sanatorio San Martin — Venado Tuerto, Santa Fe Province, Argentina
• Favaloro Foundation — Buenos Aires, Argentina
• Hospital San Roque — Córdoba, Argentina
• Westmead Hospital — Westmead, Australia
• Hospital Maternidade — Poços de Caldas, Minas Gerais, Brazil
• Sociendade Hospitalar Angelina Caron — Campina Grande do Sul, Paraná, Brazil
• Hospital Lifecenter — Belo Horizonte, Brazil
• Hospital e Maternidade Celso Pierro - PUCCAMP — Campinas, Brazil
• Hospital Barra D'Or — Rio de Janeiro, Brazil
• Hospital de Base — São José do Rio Preto, Brazil
• University of Alberta Hospital — Edmonton, Alberta, Canada
• Grey Nuns Hospital — Edmonton, Alberta, Canada
• Health Sciences Centre Winnipeg — Winnipeg, Manitoba, Canada
• Hamilton General Hospital — Hamilton, Ontario, Canada
• St. Joseph's Healthcare Hamilton — Hamilton, Ontario, Canada
• Juravinski Hospital and Cancer Centre — Hamilton, Ontario, Canada
• Kansas University Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.